- Patients with Crohn’s disease (CD) treated using a “tight control” (TC) approach based on inflammatory biomarker and clinical symptom monitoring spend less time in hospitals and more time in remission than those treated using a symptom-based clinical management (CM) approach, boosting cost-effectiveness.
Why this matters
- Physicians should consider a TC strategy when treating patients with moderate-to-severe active CD.
- Researchers analyzed data from a randomized clinical trial comparing TC with CM in patients treated with adalimumab (Humira), prednisone, and azathioprine (n=244; mean age, 31.60±11.7 years; 57.8% women; 92.6% white).
- They used regression models to predict health states, treatment effects, hospitalizations, and costs.
- Funding: AbbVie (maker of Humira), which approved and reviewed the analysis before publication.
- When compared with CM, TC was linked to a higher clinical remission rate (58.2% vs 46.8%), fewer CD-related hospitalizations (0.124 vs 0.297 times per patient), and more injections of adalimumab (mean, 31.01 vs 24.74).
- Trial data may not be generalizable to patients with long CD treatment histories.
- Cost-effectiveness analysis may not apply to countries other than the United Kingdom.